Literature DB >> 17944193

[Effect of matrine injections on invasion and metastasis of gastric carcinoma SGC-7901 cells in vitro].

Zhi-jun Dai1, Jie Gao, Wen-ying Wu, Xi-jing Wang, Zong-fang Li, Hua-feng Kang, Xiao-xu Liu, Xiao-bin Ma.   

Abstract

OBJECTIVE: To investigate the effect of matrine injections on invasion and metastasis of gastric carcinoma SGC-7901 cells in vitro.
METHODS: MTT assay was used to examine the effect of matrine injections on proliferation of SGC-7901 cells after 24, 48, 72, 96 hours treatment; Transwell chamber assay was performed to determine the effect of matrine injection on invasion and migratory capacity of the cells; Effect on adhesion potential of SGC-7901 cells was tested by cell matrigel adhesion assay.
RESULTS: Matrine injec-tions could inhibit the proliferation of SGC-7901 cells, with obvious dose-dependent and time-dependent effects. Matrine injections sig-nificantly inhibited adhesion, invasion and migration capacity of SGC-7901 cells in vitro. The inhibitory rate of them after treatment with 1.5 mg/ml matrine injections for 24 h were (45.32 +/- 3.10)%, (32.66 +/- 2.82)%, (38.35 +/- 3.41)% respectively. After treat-ment of matrine injections (1.5 mg/ml)for 24 h, the expression level of CD44(V6) in SGC-7901 cells was decreased compared with the untreated group.
CONCLUSION: Matrine injections can inhibit the migration, invasion and adhesion capacity of SGC-7901 cells in vitro. The inhibition effect may be related to down-regulating the expression of CD44(V6) protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944193

Source DB:  PubMed          Journal:  Zhong Yao Cai        ISSN: 1001-4454


  8 in total

1.  Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway.

Authors:  Liqiang Qian; Xiaqin Li; Penghui Ye; Gang Wang; Wei Dai; Yan Liu; Quangen Gao; Genhai Shen
Journal:  Cytotechnology       Date:  2017-11-23       Impact factor: 2.058

2.  TCM matrine inducescell arrest and apoptosis with recovery expression of the hepato-specific miR122a in human hepatocellular carcinomaHep G2cell line.

Authors:  Wuyuan Zhou; Xiang Xu; Jie Gao; Pengfei Sun; Lei Li; Xuetao Shi; Jie Li
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway.

Authors:  Weiru Xu; Hongsheng Lin; Ying Zhang; Xinyi Chen; Baojin Hua; Wei Hou; Xin Qi; Yingxia Pei; Xiaoyun Zhu; Zhizheng Zhao; Liangliang Yang
Journal:  J Exp Clin Cancer Res       Date:  2011-10-28

4.  Compound Radix Sophorae Flavescentis exerts antitumor effects by inhibiting the proliferation and inducing the apoptosis of esophageal carcinoma TE-8 cells.

Authors:  Xiaoyu Yang; Weimei Cai; Qinghui Yang; Zhihong Lu; Jinsong Li; Jian Yu
Journal:  Oncol Lett       Date:  2015-08-13       Impact factor: 2.967

5.  Efficacy and safety of compound Kushen injection combined with chemotherapy on postoperative Patients with breast cancer: A meta-analysis of randomized controlled trials.

Authors:  Man Ao; Xu Xiao; Qingshan Li
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

6.  Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses.

Authors:  Jing Wang; Qiuyuan Wang; Peitong Zhang; Ruoqi Zhang; Jie He
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

7.  Antitumor activities of kushen: literature review.

Authors:  Mingyu Sun; Hongyan Cao; Lin Sun; Shu Dong; Yanqin Bian; Jun Han; Lijun Zhang; Shuang Ren; Yiyang Hu; Chenghai Liu; Lieming Xu; Ping Liu
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-28       Impact factor: 2.629

8.  Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Liu Pu; Wei-Hao Chen; Lu-Xi Cao; Kun-Ji Wu; Shu-Lian Chen; Ji-Huan Lin; Cheng-Lu Li; Shi-Qi Wang; Ming-Min Zhu; Yi-Min Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-06       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.